Adagene FY26 H1 net loss widens to US$ 16.4 million; revenue turns to US$ 1.6 million

• Adagene posted a GAAP net loss attributable to shareholders of US$16.4 million for the six months ended June 30, 2026.
• Revenue was US$1.6 million, swinging from no revenue a year earlier on collaboration and technology licensing performance obligations.
• R&D expense rose 16.2% to US$14 million, while administrative costs increased to US$4.2 million from US$3.7 million.
• Cash and cash equivalents climbed to US$127.9 million from US$74.5 million, extending the projected cash runway into late 2028.
• Phase 2 MSS CRC trial remains on track with results expected in 1H 2027; Sanofi-sponsored Phase 1/2 basket dosing began.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120730PRIMZONEFULLFEED9807907) on August 12, 2026, and is solely responsible for the information contained therein.